Africa, patients with cystic fibrosis (CF) are highly susceptible to infections by multidrug-resistant isolates of
P. aeruginosa, with 60-80% of CF adults showing chronic infection by this pathogen (Parkins et al., 2018;
Hamiwe et al., 2024). As well as patients with community-acquired pneumonia (CAP) in Croatia, the rate of P.
aeruginosa CAP in patients with prior infection caused by P. aeruginosa and at least one chronic lung disease
was 67%. As mentioned by Garousi et al. (2023), in African and Western countries, the prevalence rates of P.
aeruginosa in diabetic foot ulcer infections were reported at 16.3% and 11.1% respectively. This indicates how
widespread this pathogen is globally and how it continues to be a healthcare burden.
Additionally, the prevalence of antibiotic-resistant P. aeruginosa increases morbidity, limiting treatment
options. The Pan American Health Organization/World Health Organization (PAHO/WHO) received a report
concerning surgical site infections caused by antibiotic-resistant P. aeruginosa after invasive procedures were
performed in Tijuana, Mexico (WHO, 2019). In a review, P. aeruginosa isolates from the Middle East and
North Africa region, especially Saudi Arabia, Egypt, Libya, Syria, and Lebanon showed high-level resistance
to different antibiotics, particularly in critical care units (Momenah et al., 2023). In Spain, approximately 30%
of all P. aeruginosa strains from infections acquired in Spanish ICUs are resistant to carbapenems,
ceftazidime, and quinolones. The increasing spread of highly resistant bacteria underscores the urgent need for
improved treatments and more potent therapeutic solutions.
In Southeast Asia, healthcare-acquired infections (HAI) caused by P. aeruginosa are significant health
concerns affecting vulnerable populations. Notably, HAI caused by P. aeruginosa in Southeast Asia is high, at
approximately 22%, which is at the higher end of the worldwide scale, with Indonesia having the highest
prevalence rate of HAI at 30.4% in the region. This HAI can be attributed to P. aeruginosa, which made up
13.8% of hospital-acquired pneumonia in Thailand.
This rise of P. aeruginosa infections has also exhibited antibacterial and antimicrobial resistance, making
various treatments in the region ineffective. In Indonesia alone, a total of 1554 P. aeruginosa isolates present
resistance to multiple antibiotics, including colistin, an antibiotic used for HAI, was found to be 100%
ineffective against the bacteria. Furthermore, P. aeruginosa isolates exhibited broad-spectrum resistance
(87.8% multidrug resistance) in a public acute care hospital in Singapore, remaining only susceptible to
polymyxin B (95.0%) and amikacin (55.0%). This information urges a need to address the complications and
issues caused by P. aeruginosa.
Given these concerns, the global burden of P. aeruginosa infections poses a rising challenge because of
antibiotic resistance driving the development of a wide range of strategies to address it. Fiel and Roesch (2022)
mentioned in their study that aminoglycosides like tobramycin exhibit effectiveness against the Gram-negative
bacteria, including P. aeruginosa. A study by Reynolds and Kollef (2021) also demonstrated that patients who
received 300mg of tobramycin twice daily for 28 days eradicated P. aeruginosa in more than 70% of patients
while improving lung function. To add, aminoglycosides, including amikacin, gentamicin, and tobramycin are
usually used to treat urinary tract infections caused by P. Aeruginosa.
Additionally, the presence of multiple beneficial phytochemicals in medicinal herbs like bagras aid in the
successful process of inhibiting various bacteria. From the study of Kareem et al. (2020), three varying
concentrations of bagras ethanolic extracts against another gram-negative bacterium, E. coli, resulted in 18
mm, 20.5 mm, and 22.5 mm of zone of inhibitions (ZOIs). This finding aligns with the study by Abiodun et al.
(2024), which highlighted the strong antibacterial effects of eucalyptus essential oil on several respiratory
pathogens, including E. cloacae with a mean ZOI of 23.0 mm, K. pneumoniae with 22.7 mm, and S. aureus
with 16.0 mm, at a concentration of 100mg/mL. On the other hand, makopa showed weak to no signs of the
zone of inhibitions against bacteria similar to the mentioned studies above. The makopa leaves ethanol extract
presented weak inhibitory activity against Gram-negative bacteria such as E. coli showing 7 mm ± 0.99 mm
and 9 mm ± 0.89 mm diameters of ZOIs respectively (Khandaker et al., 2015). This indicates that the bagras
leaves have a greater potential of being an antibacterial agent against pathogens compared to makopa leaves.
The Philippines has also been subjected to the spread of P. aeruginosa, contributing to the growing cases of
diseases related to the said bacteria. In post-percutaneous nephrolithotripsy, it is highlighted that P. aeruginosa
is the most common bacteria in kidney stones in the Philippines, noting its high resistance to standard
Page 681